[Federal Register Volume 86, Number 214 (Tuesday, November 9, 2021)]
[Notices]
[Page 62190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24445]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Use of 
Tomentosenol in Treating or Preventing Skin Disorders

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive, sublicensable patent license 
to University of the Sunshine Coast (``USC''), a public university 
based on the Sunshine Coast, Queensland, Australia, in its rights to 
the inventions and patents listed in the SUPPLEMENTARY INFORMATION 
section of this notice.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before November 24, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Rose M. Freel, Ph.D., Senior Licensing and 
Patenting Manager, NCI Technology Transfer Center, Telephone (301) 624-
8775 or Email: [email protected].

SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and 
foreign patents/patent applications thereof are the intellectual 
properties to be licensed under the prospective agreement to USC: 
Australian Provisional Patent Application No. 2021902329, filed Aug 3, 
2021, entitled ``Use of tomentosenol in treating or preventing skin 
disorders'' (HHS Ref. No. E-107-2021-0).
    The patent rights in these inventions have been assigned to the 
Government of the United States of America and the University of the 
Sunshine Coast. The prospective patent license will be for the purpose 
of consolidating the patent rights to USC, one of the co-owners of said 
rights, for commercial development and marketing. Consolidation of 
these co-owned rights is intended to expedite development of the 
invention, consistent with the goals of the Bayh-Dole Act codified as 
35 U.S.C. 200-212.
    The prospective patent license will be worldwide, exclusive, and 
may be limited to those fields of use commensurate in scope with the 
patent rights. It will be sublicensable, and any sublicenses granted by 
USC will be subject to the provisions of 37 CFR part 401 and 404.
    The invention pertains to tomentosenol A, a natural product that 
may be useful for treating, inhibiting, or preventing scar formation 
development or progression, reducing pre-existing scar tissue, and/or 
other fibrotic skin disorders. Based on current available data, the 
intended use for the invention is as a therapeutic in scar therapy, 
skin fibrosis, skin diseases, and inhibition of the proliferation or 
migration of skin cells.
    This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404. 
The prospective exclusive patent license will include terms for the 
sharing of royalty income with NCI from commercial sublicenses of the 
patent rights and may be granted unless within fifteen (15) days from 
the date of this published notice the NCI receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license that are timely filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive patent license. In response to this Notice, 
the public may file comments or objections. Comments and objections, 
other than those in the form of a license application, will not be 
treated confidentially, and may be made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 3, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2021-24445 Filed 11-8-21; 8:45 am]
BILLING CODE 4140-01-P